



Signatera™
Residual disease test (MRD)


Know cancer's next move with the Signatera™ Molecular Residual Disease Assay



Tumor-informed MRD testing for optimized patient management

Signatera™ is a highly sensitive and tumor-informed molecular residual disease assay (MRD) using circulating tumor DNA (ctDNA), custom designed for each patient to help inform earlier intervention.

Informing treatment decisions across the continuum of care



Setting the standard for MRD testing

Signatera™ is the most comprehensively validated and widely published MRD assay with broad patient access



Validated performance^{1,2}

Across **6,500 patients**, **>25 tumor types**, and **>65 peer-reviewed publications**

Prognostic of disease recurrence and progression; predictive of IO treatment benefit



Optimized for longitudinal monitoring

Signatera™ **quantifies ctDNA** via mean tumor molecules per mL (MTM/mL) of plasma to **assess real-time changes in disease burden**



Extensive experience helping power treatment decisions³

>200,000 Signatera™ patients
>40% of US oncologists have ordered Signatera™



Broadest payer coverage*

Signatera™ is covered by Medicare for **CRC, ovarian, breast, MIBC, and pan-cancer immunotherapy response monitoring**

Learn more at natera.com/oncology

Discover more



References: **1.** Bratman SV, Yang SYC, Iafolla MAJ, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. *Nature Cancer*. 2020;1(9):873-881. **2.** Powles T, Assaf ZJ, Davarpanah N, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. *Nature*. 2021. **3.** Natera data on file. *As of June 2023

13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | +1 844.778.4700 | natera.com

Signatera™ has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA), CAP accredited, ISO 13485 certified, and CLIA certified. © 2024 Natera, Inc. All Rights Reserved. SGN_AD_ACCC_Sept_ALTAIR_8.5x11_20240820_NAT-8021730

ONCOLOGY ISSUES

The Journal of the
Association of Cancer Care Centers

Editor-in-Chief

Mark Liu, MHA

Executive Director

Meagan O'Neill, MS

Managing Editor

Monique J. Marino

Associate Editors

Nicole Colwell, MD

Rachel Morrison Brown

Rania Emará

Molly Kisiel, MSN, FNP-BC

Rachel Radwan

EDITORIAL BOARD

Robert R. Buras, MD

Lindsey Byrne, MS, CGC

Alissa Huston, MD

Heather Jackson, PhD, APRN-BC, NEA-BC, FAANP

Sarah Jax, RN, MA, CNP, AOCNP

Jeffrey Kendall, PsyD

Keri Michalilik, MHA, BSN

Krista Nelson, LCSW, OSW-C, BCD, FAOSW, ACCCC

Emily Touloukian, DO

ACCC EXECUTIVE COMMITTEE

President

Nadine J. Barrett, PhD, MA, MS, FACCC

President – Elect

Una Hopkins, RN, FNP-BC, DNP, FACCC

Treasurer

Douglas B. Flora, MD, LSSBB, FACCC

Secretary

Jorge Garcia, PharmD, MS, MHA, MBA, FACHE, FACCC

Immediate Past President

Olalekan Ajayi, PharmD, MBA, FACCC

Trustees

Jennifer Bires, MSW, LCSW, OSW-C, FACCC

JiaJoyce Conway, DNP, CRNP, AOCNP

Renea Duffin, MPA

Matthew Manning, MD, FASTRO, FACCC

Laillea Noel, PhD, MSW

Kurt Oettel, MD

Lori Schneider, FACCC

Leigha Senter-Jamieson, MS, LGC

Afreen Idris Shariff, MD, MBBS

Cardinale B. Smith, MD, PhD

Oncology Issues serves the multidisciplinary specialty of oncology care and cancer program management.

Oncology Issues (ISSN: 1046-3356) is published bimonthly for a total of 6 issues per year by the Association of Cancer Care Centers (ACCC), 1801 Research Blvd, Suite 400, Rockville, MD 20850-3184, USA. Copyright © 2024 by the Association of Cancer Care Centers. All rights reserved. No part of this publication may be reproduced, stored, transmitted, or disseminated in any form or by any means without prior written permission from the publisher.

FROM THE EDITOR

2024 Trending Now in Cancer Care

BY MARK LIU, MHA



The landscape of cancer care is evolving rapidly and ACCC's **2024 Trending Now in Cancer Care** [report](#) offers a comprehensive glimpse into the transformative forces shaping our field. From the rise of artificial intelligence to over-

coming workforce challenges and advancing precision medicine, this year's insights reveal critical developments that will undoubtedly define the future of oncology. I am both inspired and challenged by the dynamic opportunities these innovations present.

At Mount Sinai, we are actively engaging with many of these emerging trends, particularly the integration of AI and machine learning across care services. Thinking through the ability of AI to streamline administrative tasks, analyze complex data, and enhance predictive tools is already helping us improve our care delivery. However, as highlighted in the ACCC report, we must be vigilant in ensuring that these technologies are used safely, ethically, and with the highest standards of patient care in mind. While AI offers incredible promise, careful validation and the avoidance of bias are paramount as we adopt these tools in clinical practice.

One of the most exciting developments highlighted in this year's report is the growing emphasis on precision medicine and personalized care. The ability to tailor treatments based on a patient's unique genetic makeup is transforming how we approach cancer care. It's important when you are expanding your precision medicine program to ensure that more patients benefit from targeted therapies, from early biomarker testing, and from integration of the latest genomic discoveries into treatment plans. However, as the report underscores, the challenge lies in ensuring consistent access to these advanced therapies, particularly for underserved populations, which may lead to disparities in care.

The oncology workforce shortage is another area where the report's findings are hitting close to home. With the rising complexity of cancer

treatments, clinicians are stretched, making it more critical than ever to support our teams. At Mount Sinai, we've been focused on addressing burnout by enhancing workflows, providing continuous education on new therapies, and promoting multidisciplinary collaboration—all themes underscored in ACCC's **2024 Trending Now in Cancer Care** report.

For more, listen to ACCC executive director, Meagan O'Neill's **CANCER BUZZ** [podcast](#). About the topic of AI, O'Neill had this to say, "ACCC starting is with the here and now. So, what's available today that has been proven to save time or reduce burnout or be an effective tool for better patient care, for better access. Those solutions are what we're focused on this year and into 2025 so that we can help our members cut through the noise in this space."

As we look ahead, these trends are not just industry buzzwords—they are the blueprint for the future of cancer care. I encourage you to join the conversation and contribute to the evolving landscape by attending the 51st Annual Meeting & Cancer Center Business Summit (AMCCBS), in Washington DC, March 5-7, 2025. Together, we can drive forward the innovations that will shape the next chapter of oncology and make a meaningful difference in the lives of our patients. 